Site & Patient Solutions case studies

Explore our library of case studies for patient centric clinical trial services.

An end-to-end solution providing the support and structure to efficiently operationalise clinical trials. Site & Patient Solutions offers faster study start-up, increased patient enrolment and retention, and site training and support to ensure compliance, quality data and inspection readiness.

Increased compliance for complex Alzheimer’s disease study

The sponsor in this case was a large pharmaceutical company that contracted ICON to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.

In-Home Services: Trial continuity during COVID-19

A biopharmaceutical company was running a global 4-study program evaluating the long-term safety and effectiveness of a study drug in adult patients with a rare, inherited disease impacting the kidneys and other vital organs.

Flexible and meticulous management

A large pharma sponsor was conducting a Phase 2/3 randomised, placebo-controlled COVID-19 vaccine study. Facing labour and supply shortages, as well as unprecedented safety challenges due to the ongoing pandemic, the sponsor contracted Accellacare to support their staffing, enrollment, and logistics across seven US sites.

In-Home Services: Rescue: accelerated patient recruitment

A biotechnology company was attempting to recruit 40 paediatric patients in a US phase II oncology study.

In-Home Services: Patient satisfaction levels in rare disease

Large pharmaceutical company was running a phase II study to assess the efficacy of a study drug in paediatric patients with a rare degenerative genetic disorder. The study required weekly infusions for more than 50 patients in the UK.

Overcoming challenges in non small cell lung carcinoma rescue study

A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.

Patient insights & strategy

We developed and facilitated a series of Patient Partner Workshops™. Patients engaged in a variety of unique activities designed to stimulate open, honest dialogue among the group.

Agile operations drive enrollment in COVID-19 treatment studies

A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.

Overcoming recruitment challenges

ICON partnered with a drug development sponsor to conduct a multicenter, randomised, double-blind, placebo-controlled,
proof of concept study of the efficacy and safety of a treatment for patients with fibromyalgia.

In-Home Services: Special populations and procedures

A global biopharmaceutical company was conducting a set of post-marketing studies to determine the safety and transference of a drug taken for autoimmune disorders during pregnancy and breastfeeding.

In-Home Services: Improved site productivity

A mid-size pharmaceutical company conducted a phase II study to compare treatments in 52 adult patients with plaque psoriasis. The treatment was to be applied twice daily for 3 weeks in 10 US sites.

Large global cardiovascular outcome program

ICON was engaged by a large pharma sponsor late in the study process to provide solutions to support the recruitment of 28,000 patients for two global mega Cardiovascular Outcome studies. ICON developed and implemented an plan including recruitment and retention planning, tactical implementation, vendor oversight processes and direct site support to ensure key milestones were met.